Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 74.8% in September

Exicure, Inc. (NASDAQ:XCUR) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 32,600 shares, a decrease of 74.8% from the August 31st total of 129,500 shares. Based on an average daily trading volume, of 1,340,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 4.9% of the company’s shares are short sold.

Insider Transactions at Exicure

In related news, major shareholder Co. Ltd. Dgp purchased 237,223 shares of Exicure stock in a transaction on Thursday, September 12th. The stock was acquired at an average cost of $3.00 per share, for a total transaction of $711,669.00. Following the completion of the acquisition, the insider now owns 849,223 shares of the company’s stock, valued at approximately $2,547,669. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 3.90% of the stock is currently owned by corporate insiders.

Exicure Trading Down 8.2 %

NASDAQ:XCUR opened at $3.70 on Wednesday. The stock has a market capitalization of $32.01 million, a price-to-earnings ratio of -2.43 and a beta of 1.24. The firm has a fifty day simple moving average of $0.93 and a two-hundred day simple moving average of $0.39. Exicure has a 12 month low of $1.44 and a 12 month high of $6.00.

Exicure (NASDAQ:XCUR) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.01) EPS for the quarter.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.